Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fi...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2020]
|
| In: |
Respiratory research
Year: 2020, Jahrgang: 21 |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-019-1269-6 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-019-1269-6
|
| Verfasserangaben: | Claudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, Manuel Quaresma, Susanne Stowasser, Michael Kreuter |
| Zusammenfassung: | The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fibrosing interstitial lung diseases. |
|---|---|
| Beschreibung: | Gesehen am 30.03.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-019-1269-6 |